Human cancer typically exhibits an alteration of the RAS‐RAF‐MEK‐ERK‐MAPK (RAS‐MAPK) pathway as a result of aberrant receptor tyrosine kinase activation or gain of function mutations, mainly in the RAS or RAF genes.35 The gene discussed is RAF1; the disease is cancer.